Meta-analysis of risk factors for thrombocytopenia related to linezolid

Abstract

Objective To evaluate the risk factors for thrombocytopenia related to linezolid (LZD) comprehensively. Methods The related databases were electronically searched for the case-control studies about risk factors for LZD-associated thrombocytopenia from the inception to June 2016. The quality of the literature which was enrolled into the Meta-analysis evaluated by Newcastle-Ottawa Quality Assessment Scale (NOS), and then Meta-analysis was conducted using RevMan 5.3 software. The results are presented as odds risk (OR) and 95% confidence interval (CI). Results A total of 25 studies involving 4 279 patients were entered, including 1 335 in the thrombocytopenia group and 2 944 in the none thrombocytopenia group. The NOS scores of all literature were greater than or equal to 7. The result of Meta-analysis showed that, the baseline platelet count 14 days (OR=1.76, 95%CI: 1.17-2.65, P=0.006) and age≥65 years (OR=1.54, 95%CI: 1.03-2.31, P=0.04) were identified as significant risk factors for LZD-associated thrombocytopenia. Conclusion Current evidence shows that the severe damage to renal function, low baseline platelet count, low body weight, long-term LZD administration and advanced age are risk factors of LZD-related thrombocytopenia. Key words: Linezolid; Thrombocytopenia; Risk factor; Meta-analysis